Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

In Brief: Sonus Pharmaceuticals' EchoGen

  • News

Executive Summary

Sonus Pharmaceuticals' EchoGen: NDA submitted Aug. 12 for perflenapent emulsion, a fluorocarbon-based ultrasound contrast agent. Filing triggers $4 mil. milestone payment from U.S. marketer Abbott Labs. Sonus also recently earned a $3 mil. milestone payment from Daiichi, which will market and distribute product in Pacific Rim. According to Bothell, Wash.-based Sonus, EchoGen has a diagnostic sensitivity of 89%, specificity of 97%, a positive predictive value of 98%, negative predictive value of 84% and an overall accuracy of 92%...

Table

View full table

Tags:
Latest Headlines

Priority Review Vouchers: Tropical Disease Candidates Wait Years For FDA Action On Qualifying List

Pink Sheet Podcast: US FDA Biosimilar Strategy, Gene Therapy Accelerated Approvals, FDA v. Partisan Politics

Idorsia’s Novel Hypertension Pill Among Eight New Drugs To Win EMA Nod

AI Used In Drug R&D Likely Exempt From Tough EU AI Rules, Says EFPIA

See All
UsernamePublicRestriction

Register

PS028824

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By